论文部分内容阅读
采用焙烧还原法制备了牛磺酸/层状双氢氧化物插层复合物(TAU-LDH)和布洛芬/层状双氢氧化物插层复合物(IBU-LDH)。研究了插层复合物中TAU和IBU在模拟人体内肠道pH值(pH=7.4)的磷酸缓冲溶液(PBS)中的缓释性能。XRD和FT-IR分析表明,TAU和IBU阴离子成功进入到LDHs层间形成插层复合物,IBU-LDH插层复合物的结晶性能优于TAU-LDH。UV-Vis分析表明,存在于LDHs层间的TAU和IBU在缓冲溶液中具有明显的缓释特性。复合物中的TAU 40 min释放85%,180 min释放完全;IBU 40 min释放88%,180 min释放完全。IBU-LDH插层复合物的药物缓释特性优于TAU-LDH插层复合物。
Taurine / Layered Double Hydroxide Intercalation Complex (TAU-LDH) and Ibuprofen / Layered Double Hydroxide Intercalation Complex (IBU-LDH) were prepared by roasting and reduction method. The sustained-release properties of TAU and IBU in phosphate buffered saline (PBS) simulating human intestinal pH (pH = 7.4) were investigated in intercalation complexes. The results of XRD and FT-IR indicated that the anions of TAU and IBU successfully entered the interlayer of LDHs to form intercalation complexes. The crystallinity of IBU-LDH intercalation complexes was better than that of TAU-LDH. UV-Vis analysis showed that the TAU and IBU existing in the LDHs layer had obvious sustained-release characteristics in the buffer solution. The TAU in the composite was 85% released for 40 min and completely released after 180 min. The release of 88% IBU for 40 min was completely released after 180 min. IBU-LDH intercalation complex drug release characteristics than TAU-LDH intercalation complexes.